A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Ipatasertib in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Ipatasertib (Primary)
- Indications Breast cancer; Gastrointestinal cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 22 Jan 2018 Planned End Date changed from 17 May 2018 to 31 May 2018.
- 22 Jan 2018 Planned primary completion date changed from 17 May 2018 to 31 May 2018.
- 17 Nov 2017 New trial record